GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CFO Kevin Feeley sold 3,729 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total value of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares in the company, valued at approximately $2,428,004.58. This represents a 8.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kevin Feeley also recently made the following trade(s):
- On Tuesday, June 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $53.77, for a total transaction of $68,072.82.
- On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48.
GeneDx Price Performance
Shares of GeneDx stock opened at $59.01 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -22.02 and a beta of 1.96. The firm’s 50-day moving average is $54.25 and its two-hundred day moving average is $86.49. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87.
More GeneDx News
Here are the key news stories impacting GeneDx this week:
- Negative Sentiment: Multiple law firms are advertising a securities class action against GeneDx, with a lead-plaintiff deadline of August 3, 2026, alleging material misstatements and omissions about the viability of the Fabric Genomics acquisition. GeneDx securities fraud class action lawsuit filed
- Negative Sentiment: Several follow-up notices emphasize the alleged 49% stock decline after GeneDx’s Q1 2026 earnings report and a 94% write-off related to the acquisition, reinforcing concerns about execution and disclosure risk. Hagens Berman class action alert
- Neutral Sentiment: GeneDx disclosed insider sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to cover tax withholding obligations tied to vesting equity awards, which makes the transactions less alarming on their own. CEO SEC filing CFO SEC filing
- Positive Sentiment: GeneDx appointed Mark Gardner as company president, a leadership move that could improve execution and strategic focus over time. GeneDx appoints new president
Wall Street Analysts Forecast Growth
WGS has been the subject of a number of analyst reports. BTIG Research lowered their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Craig Hallum reissued a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Wells Fargo & Company restated an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Guggenheim dropped their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.
Get Our Latest Analysis on WGS
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Royal Bank of Canada boosted its stake in GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after acquiring an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of GeneDx by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of GeneDx in the 2nd quarter worth $249,000. Institutional investors own 61.72% of the company’s stock.
About GeneDx
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
